$MTEM
Molecular Templates, Inc.

2015 Q2 Form 10-Q Financial Statement

#000156459015005863 Filed on July 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $3.680M $3.680M
YoY Change 0.0% 15.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.480M $2.480M
YoY Change 0.0% 14.29%
% of Gross Profit
Research & Development $10.14M $8.664M
YoY Change 17.05% 8.53%
% of Gross Profit
Depreciation & Amortization $260.0K $340.0K
YoY Change -23.53% 0.0%
% of Gross Profit
Operating Expenses $12.62M $11.14M
YoY Change 13.28% 9.77%
Operating Profit -$8.941M
YoY Change
Interest Expense $39.00K $30.00K
YoY Change 30.0% -11.76%
% of Operating Profit
Other Income/Expense, Net $596.0K $6.665M
YoY Change -91.06% -214.52%
Pretax Income -$8.310M -$770.0K
YoY Change 979.22% -93.96%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.306M -$766.0K
YoY Change 984.33% -94.01%
Net Earnings / Revenue -225.71% -20.82%
Basic Earnings Per Share -$0.12 -$0.01
Diluted Earnings Per Share -$0.12 -$0.12
COMMON SHARES
Basic Shares Outstanding 71.33M 59.35M
Diluted Shares Outstanding 72.82M 63.00M

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.00M $63.00M
YoY Change 6.35% -35.85%
Cash & Equivalents $10.57M $6.463M
Short-Term Investments $56.50M $56.60M
Other Short-Term Assets $1.500M $2.800M
YoY Change -46.43% 47.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $72.20M $70.10M
YoY Change 3.0% -31.72%
LONG-TERM ASSETS
Property, Plant & Equipment $424.0K $700.0K
YoY Change -39.43% -9.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $12.20M
YoY Change -100.0%
Other Assets $1.264M $1.200M
YoY Change 5.33% 13.31%
Total Long-Term Assets $1.654M $14.10M
YoY Change -88.27% 669.65%
TOTAL ASSETS
Total Short-Term Assets $72.20M $70.10M
Total Long-Term Assets $1.654M $14.10M
Total Assets $73.85M $84.20M
YoY Change -12.29% -19.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $635.0K $2.900M
YoY Change -78.1% 228.05%
Accrued Expenses $2.451M $9.700M
YoY Change -74.73% 375.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.53M $27.30M
YoY Change -6.49% 20.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $74.60M $85.10M
YoY Change -12.34% -20.47%
Total Long-Term Liabilities $74.60M $85.10M
YoY Change -12.34% -20.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.53M $27.30M
Total Long-Term Liabilities $74.60M $85.10M
Total Liabilities $100.2M $112.4M
YoY Change -10.89% -13.35%
SHAREHOLDERS EQUITY
Retained Earnings -$392.7M
YoY Change
Common Stock $366.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$26.30M -$28.30M
YoY Change
Total Liabilities & Shareholders Equity $73.85M $84.20M
YoY Change -12.29% -19.43%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$8.306M -$766.0K
YoY Change 984.33% -94.01%
Depreciation, Depletion And Amortization $260.0K $340.0K
YoY Change -23.53% 0.0%
Cash From Operating Activities -$15.87M -$10.81M
YoY Change 46.81% 71.59%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$150.0K
YoY Change -86.67% 66.67%
Acquisitions
YoY Change
Other Investing Activities $5.380M $10.65M
YoY Change -49.48% -204.11%
Cash From Investing Activities $5.370M $10.50M
YoY Change -48.86% -201.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 20.00K
YoY Change -100.0% -97.01%
NET CHANGE
Cash From Operating Activities -15.87M -10.81M
Cash From Investing Activities 5.370M 10.50M
Cash From Financing Activities 0.000 20.00K
Net Change In Cash -10.50M -290.0K
YoY Change 3520.69% -98.18%
FREE CASH FLOW
Cash From Operating Activities -$15.87M -$10.81M
Capital Expenditures -$20.00K -$150.0K
Free Cash Flow -$15.85M -$10.66M
YoY Change 48.69% 71.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 thld Collaboration Receivable
CollaborationReceivable
3647000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1264000
CY2015Q2 us-gaap Assets
Assets
73854000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
635000
CY2015Q2 thld Accrued Clinical And Development Liabilities
AccruedClinicalAndDevelopmentLiabilities
7720000
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
169000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
71000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
366366000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2451000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
424000
CY2015Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
19627000
CY2015Q2 us-gaap Contracts Revenue
ContractsRevenue
3680000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
12621000
CY2014Q4 thld Collaboration Receivable
CollaborationReceivable
7248000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
25528000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71334779
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
11141000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71334779
us-gaap Net Income Loss
NetIncomeLoss
-19460000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-766000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8664000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2480000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8941000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2477000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8309000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392722000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6665000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
-26303000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73854000
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Contracts Revenue
ContractsRevenue
7361000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
596000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-976000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8122000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6463000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14722000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-8306000
CY2015Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
54833000
us-gaap Share Based Compensation
ShareBasedCompensation
3316000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-974000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1997000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
8214000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
30907000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
30355000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6630000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28514000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
374000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28514000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
374000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2178000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-816000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7279000
CY2015Q2 us-gaap Liabilities
Liabilities
100157000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59347000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69046000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59325000
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62998000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69046000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63433000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
503000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
726000
us-gaap Share Based Compensation
ShareBasedCompensation
2734000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
8122000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-14000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3601000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-13831000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
773000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
699000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1439000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1202000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
1722000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-271000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-729000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-650000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
74000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-34000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7361000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7361000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19706000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6451000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
39479000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
33137000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5261000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
50209000
CY2015Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15997000
CY2015Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1481000
CY2014Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3651000
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
4108000
CY2015Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-308000
CY2014Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-6665000
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-8122000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8614000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7431000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19460000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8300000
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8300000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28100000
CY2015Q1 thld Warrants Initial Exercise Price
WarrantsInitialExercisePrice
10.86
CY2015Q1 thld Warrant Maximum Adjusted Exercise Price
WarrantMaximumAdjustedExercisePrice
10.86
CY2015Q1 thld Warrant Minimum Adjusted Exercise Price
WarrantMinimumAdjustedExercisePrice
3.62
CY2015Q1 thld Warrant Term
WarrantTerm
P5Y
CY2015Q1 thld Warrants Twenty Day Vwap Exceeds
WarrantsTwentyDayVWAPExceeds
18.00
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3961000
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
14692000
CY2015Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
19627000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1895000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1468000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3316000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2734000
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2015Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
17000
CY2014Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
19000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
41000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
55000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8168942
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2105500
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
61873
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
61333
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10151236
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10051806
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6032323
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.69
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.38
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.88
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.83
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.83
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M22D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M27D
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8726000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8714000
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8158000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
66758000
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
56468000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2015Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
56450000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
50222000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000
CY2014Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P4M3D
CY2015Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
30709000
CY2015Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
22000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
375000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
768000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
260000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1403000

Files In Submission

Name View Source Status
0001564590-15-005863-index-headers.html Edgar Link pending
0001564590-15-005863-index.html Edgar Link pending
0001564590-15-005863.txt Edgar Link pending
0001564590-15-005863-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10q_20150630.htm Edgar Link pending
thld-20150630.xml Edgar Link completed
thld-20150630.xsd Edgar Link pending
thld-20150630_cal.xml Edgar Link unprocessable
thld-20150630_def.xml Edgar Link unprocessable
thld-20150630_lab.xml Edgar Link unprocessable
thld-20150630_pre.xml Edgar Link unprocessable
thld-ex10_75.htm Edgar Link pending
thld-ex31_7.htm Edgar Link pending
thld-ex31_9.htm Edgar Link pending
thld-ex32_6.htm Edgar Link pending
thld-ex32_8.htm Edgar Link pending